Botanical species · safety record

Dysphania chilensis

The EFSA Compendium of Botanicals holds 9 constituent measurements for Dysphania chilensis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Dysphania chilensis (Schrad.) Mosyakin & Clemants

9Constituent measurements

0Safety records

5Cited sources

0Licensed products (Canada)

Also recorded as

Chenopodium ambrosioides var. anthelminticum (L.) A.Gray

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Ascaridol	Unspecified	Essential oil	1.1 Percent	GC-MS	Resolve DOI
(-)-camphor	Live plants	Essential oil	—	—	No resolvable identifier
Ascaridol	Fruit unspecified	Essential oil	≥ 31 Percent	Gaschromatography (GC)	No resolvable identifier
Ascaridol	Live plants	Essential oil	≤ 90 Gram/100 gram	—	No resolvable identifier
Ascaridol	Live plants	Essential oil	≥ 44.4 Gram/100 gram	—	No resolvable identifier
Ascaridol	Live plants	Essential oil	≤ 45 Percent	Unspecified	No resolvable identifier
Ascaridol	Fruit unspecified	Essential oil	≤ 69 Percent	Gaschromatography (GC)	No resolvable identifier
Ascaridol	Live plants	Essential oil	≥ 42 Percent	Unspecified	No resolvable identifier
Pinocarvone	Leaves	Essential oil	1 Percent	GC-MS	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Iwasa, Junzo., Wada, Shusuke., Fukuda, Tomoaki., Katsura, Taeko. Histochemical studies on plant components. II. Distribution of chenopodium oil and ascaridole in American wormseed. Japan. j. pharmacognosy, 1954, vol. 1953-1954, 7-8, p. 52-4.
Shapter, R. E. A preliminary investigation of the yield and composition of the oil distilled from Chenopodium ambrosioides (Linn.) var. anthelminticum (Gray). Journal of the council for scientific and industrial research (australia), 1941, vol. 14, p. 201-8.
Gbolade, Adebayo A., Tira-Picos, Vania., Nogueria, Jose M. F. CHEMICAL CONSTITUENTS OF Chenopodium ambrosioides var. anthelminticum HERB ESSENTIAL OIL FROM NIGERIA . Chemistry of natural compounds, 2010, vol. 46, no. 4, p. 654-655. DOI
Jirovetz, L., Buchbauer, G., Fleischhacker, W., Kaul, V.K. Analysis of the essential oil of the leaves of the medicinal plant Chenopodium ambrosioides var. anthelminticum (L.) A. Gray from India. Scientia pharmaceutica, 2000, vol. 68, no. 1, p. 123-128.
Wirth, Elmer Hauser. A study of Chenopodium ambrosioides, Var. anthelminticum. and its volatile oil. Journal of the american pharmaceutical association (1912-1977), 1920, vol. 9, p. 127-41.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature